![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CEL-SCI Receives U.S. Patent on Pre-Sensitizing Cancer Prior to Treatment
CEL-SCI Receives U.S. Patent on Pre-Sensitizing Cancer Prior to Treatment
June 1, 2005
CEL-SCI has been issued a U.S. patent, titled "A Method of Pre-Sensitizing Cancer Prior to Treatment With Radiation and/or Chemotherapy and a Novel Cytokine Mixture," covering its cancer drug, Multikine.
This invention relates to a breakthrough method for presensitizing cancer with Multikine prior to a therapeutic treatment, such as chemotherapy, radiation therapy or immunotherapy. CEL-SCI's drug Multikine is effective in inducing cancerous cells' entry into the cell cycle phase thereby increasing their vulnerability to treatment.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct